Relation between mean platelet volume and effectiviness of platelet rich plasma

Abstract

Objective. Investigation of the relationship between mean platelet volume (MPV) and clinical outcomes after platelet-rich plasma (PRP) applications in patients with early stage gonarthrosis.
Material and Methods. 67 Patients with stage I-II gonarthrosis who underwent PRP were evaluated retrospectively. Platelet counts and MPV values were determined in the blood samples before PRP administration. Platelet counts and MPV in PRP were determined after PRP preparation. Knee Society Scores, Functional Knee Society Scores and VAS scores were determined before and 1 year after PRP administration.
The results were evaluated by Paired t Test and Pearson Correlation analysis. Results. In blood samples, the platelet count was 216,10±62,75 103/uL MPV 10,22±1,05fL. The mean platelet count was 1350,8± 727,05 103/uL and MPV was 10,76±1,22fL in PRP. The mean Knee Society Score was 56,6±13,8 and the Functional Knee Society Score was 56,5±10 before PRP administration. The mean pre-treatment VAS score was 9,1±0,9. In the final follow-up, the mean Knee Society score was 78,8±10,4, and the Functional Knee Society Score increased to 74,9 ± 12,4. The mean VAS score was 3,5±1,4. The increase in the Knee Society Scores and Functional Knee Society Scores in the last controls was statistically significant and the decrease in the VAS scores was statistically significant (p≤0.05). In the statistical analysis of platelet counts and MPV values, it was determined that the platelet counts and MPV values in the PRP content were statistically higher than the values in the first sample (p ≤0,05). The correlation between the clinical results and MPV and platelet counts was not statistically significant (p≥0.05).
Conclusion. PRP is an alternative treatment method in early stage gonarthrosis. We found no relationship between platelet counts and MPV with clinical outcomes.

Key words:

knee, platelet-rich plasma, mean platelet volume

Read in the full issue (PDF)